Results 191 to 200 of about 1,580,389 (288)

Direct Recycling of Mixed‐Oxide Cathodes: Balancing Cost, Performance and Environmental Trade‐Offs

open access: yesAdvanced Science, EarlyView.
Direct regeneration routes for mixed‐oxide lithium‐ion battery cathodes are systematically compared using harmonized techno‐economic, electrochemical, and environmental metrics. Solid‐state, hydrothermal, molten salt, electrochemical, and chemical relithiation methods are benchmarked to identify performance, cost, and sustainability trade‐offs.
Evgenii Beletskii   +8 more
wiley   +1 more source

CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity

open access: yesAdvanced Science, EarlyView.
HEK‐293T‐derived CD3ε Nb‐engineered EVs to generate dual‐targeting CAR‐T cells directly in vivo. These EVs selectively deliver CAR.BiTE transgenes into T cells and reprogramed to HLA‐G/PD‐L1‐targeting effector cells with enhanced memory and persistence.
Shi‐Wei Huang   +27 more
wiley   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao   +24 more
wiley   +1 more source

ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion

open access: yesAdvanced Science, EarlyView.
ZBTB21 is a transcription factor that epigenetically suppresses pyroptosis and MHC‐I antigen presentation, enabling tumor immune evasion. Genetic ablation of ZBTB21 activates pyroptotic cell death and enhances antigen presentation, recruiting CD8+ T cells to overcome immune checkpoint blockade resistance.
Lei Zhao   +12 more
wiley   +1 more source

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

open access: yesAdvanced Science, EarlyView.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang   +21 more
wiley   +1 more source

Trackable Tolerogenic Macrophages Integrate PD‐L1 and Rapamycin Signaling to Suppress Alloimmune Responses in Transplantation

open access: yesAdvanced Science, EarlyView.
We developed a macrophage‐based therapeutic platform, termed trackable tolerogenic macrophages (TTM), for dual‐function immunomodulation and visualization in vivo. TTM cells were engineered to overexpress PD‐L1, incorporate bioorthogonal cell surface tags, and load rapamycin for sustained release.
Yihui Wang   +14 more
wiley   +1 more source

RENAL‐CHIP: Rejection Evaluation via Non‐Invasive Analysis of Circulating Podocytes With Herringbone‐Chip Isolation Platform

open access: yesAdvanced Science, EarlyView.
RENAL‐CHIP converts 1 mL of peripheral blood into a biopsy‐equivalent readout of renal‐allograft fate. By magnetic capture and release of donor‐derived circulating podocytes through a herringbone microfluidic chip, 84% capture, 96% release and single‐cell RNA evidence of rejection‐specific immunity are achieved.
Juan Song   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy